UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer

Current oncology (Toronto), 2018-06, Vol.25 (Suppl 1), p.S94-102

2018

Volltextzugriff (PDF)

45P Pembrolizumab versus best supportive care survival outcomes in ECOG performance status 2 NSCLC patients

Annals of oncology, 2022-04, Vol.33, p.S53

2022

Volltextzugriff (PDF)

P63.13 Long Term Survival Characteristics in SCLC Patients Receiving Atezolizumab and Chemotherapy

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1187-S1188

2021

Volltextzugriff (PDF)

EP08.02-014 Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S402-S403

2022

Volltextzugriff (PDF)

EP08.01-004 Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S336-S337

2022

Volltextzugriff (PDF)

EP05.02-001 Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S282-S283

2022

Volltextzugriff (PDF)

EP06.01-003 Impact of COVID-19 on Lung Cancer Patients; The Patients’ Perspective

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S302-S303

2022

Volltextzugriff (PDF)

EP02.04-003 A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S232

2022

Volltextzugriff (PDF)

EP08.02-071 Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S434

2022

Volltextzugriff (PDF)

EP08.02-013 Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S402

2022

Volltextzugriff (PDF)

P2.05-03 Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S308

2023

Volltextzugriff (PDF)

EP08.04-01 Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S590-S591

2023

Volltextzugriff (PDF)

1536P Synthetic control arm (SCA) analysis of lurbinectedin compared to the standard of care (SoC) among patients with small cell lung cancer (SCLC) previously treated with platinum-based chemotherapy

Annals of oncology, 2022-09, Vol.33, p.S1249

2022

Volltextzugriff (PDF)

P59.29 Frequency of PIK3CA Mutations and Therapeutic Outcomes in NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1161-S1162

2021

Volltextzugriff (PDF)

EP11.03-02 Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S619-S620

2023

Volltextzugriff (PDF)

EP10.01-008 Examining Social Determinants of Health Among Newly Diagnosed Lung Cancer Patients Contacted for Early Specialist Palliative Care Consultation

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S503-S504

2022

Volltextzugriff (PDF)

P09.08 Age-Related Outcomes of First-Line Pembrolizumab in a Real-World Non-Small-Cell Lung Cancer (NSCLC) Cohort

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S290-S290

2021

Volltextzugriff (PDF)

MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S159

2023

Volltextzugriff (PDF)

425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents

Annals of oncology, 2020-11, Vol.31, p.S1408-S1408

2020

Volltextzugriff (PDF)

1046P Outcomes of patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials

Annals of oncology, 2020-09, Vol.31, p.S717-S717

2020

Volltextzugriff (PDF)

Healthy Lives, Healthy People: the government's tobacco plan

Practice nursing, 2011-04, Vol.22 (4), p.210-210

Pabani, Aysha

2011

Volltextzugriff (PDF)

Who makes the renal outpatient clinic work?

Journal of renal nursing, 2011-05, Vol.3 (3), p.134-136

S Pabani, Aysha

2011

Volltextzugriff (PDF)

Decisions of parents regarding immunization for children 0 to 36 months old

Pabani, Munira A

2009

Volltextzugriff (PDF)

A note on special photographic techniques applicable to photoelasticity

Journal of strain analysis, 1975-07, Vol.10 (3), p.163-166

1975

Volltextzugriff (PDF)

Personal monitor for uranium and thorium in uranium mine dust

Nuclear tracks, 1979-01, Vol.3 (4), p.223-226

1979

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Englisch
(109)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(32)
Oncology
(21)
Humans
(16)
General & Internal Medicine
(10)
Medicine, General & Internal
(10)
Immunotherapy
(9)
Patients
(9)
Technology
(9)
Middle Aged
(7)
Immune Checkpoint Inhibitors
(6)
Adult
(5)
Aged
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Cardiology
(5)
Clinical Trials
(5)
Engineering
(5)
Engineering, Electrical & Electronic
(5)
Female
(5)
Lung Cancer
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer

45P Pembrolizumab versus best supportive care survival outcomes in ECOG performance status 2 NSCLC patients

P63.13 Long Term Survival Characteristics in SCLC Patients Receiving Atezolizumab and Chemotherapy

EP08.02-014 Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort

EP08.01-004 Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab

EP05.02-001 Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort

EP06.01-003 Impact of COVID-19 on Lung Cancer Patients; The Patients’ Perspective

EP02.04-003 A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases

EP08.02-071 Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort

EP08.02-013 Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC

P2.05-03 Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort

EP08.04-01 Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab

1536P Synthetic control arm (SCA) analysis of lurbinectedin compared to the standard of care (SoC) among patients with small cell lung cancer (SCLC) previously treated with platinum-based chemotherapy

P59.29 Frequency of PIK3CA Mutations and Therapeutic Outcomes in NSCLC

EP11.03-02 Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions

EP10.01-008 Examining Social Determinants of Health Among Newly Diagnosed Lung Cancer Patients Contacted for Early Specialist Palliative Care Consultation

P09.08 Age-Related Outcomes of First-Line Pembrolizumab in a Real-World Non-Small-Cell Lung Cancer (NSCLC) Cohort

MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study

425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents

1046P Outcomes of patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials

Healthy Lives, Healthy People: the government's tobacco plan

Who makes the renal outpatient clinic work?

Decisions of parents regarding immunization for children 0 to 36 months old

A note on special photographic techniques applicable to photoelasticity

Personal monitor for uranium and thorium in uranium mine dust

Suchergebnisse filtern